Federated Hermes
RCKT icon

Federated Hermes’s Rocket Pharmaceuticals RCKT Stock Holding History

Federated Hermes’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.88M Buy
2,304,207
+1,280,460
+125% +$4.26M 0.01% 758
2026
Q1 		$3.67M Buy
1,023,747
+142,498
+16% +$566K 0.01% 857
2025
Q4 		$3.09M Buy
881,249
+253,682
+40% +$869K 0.01% 876
2025
Q3 		$2.05M Buy
627,567
+3,264
+0.5% +$10.3K ﹤0.01% 924
2025
Q2 		$1.53M Buy
624,303
+209,806
+51% +$1.06M ﹤0.01% 1002
2025
Q1 		$2.76M Buy
+414,497
New +$4.1M 0.01% 861
2023
Q4 		– Sell
-5,197
Closed -$106K – 2178
2023
Q3 		$106K Sell
5,197
-4,284
-45% -$77.9K ﹤0.01% 1600
2023
Q2 		$188K Sell
9,481
-1,701
-15% -$34.4K ﹤0.01% 1559
2023
Q1 		$192K Buy
11,182
+2,028
+22% +$39.7K ﹤0.01% 1591
2022
Q4 		$179K Buy
9,154
+2,333
+34% +$43K ﹤0.01% 1574
2022
Q3 		$109K Sell
6,821
-276,303
-98% -$4.31M ﹤0.01% 1605
2022
Q2 		$3.9M Sell
283,124
-144,727
-34% -$1.73M 0.01% 748
2022
Q1 		$6.79M Buy
+427,851
New +$7.39M 0.02% 708
2021
Q2 		– Sell
-9,338
Closed -$414K – 2309
2021
Q1 		$414K Sell
9,338
-6,791
-42% -$373K ﹤0.01% 1600
2020
Q4 		$885K Sell
16,129
-177,497
-92% -$6.47M ﹤0.01% 1366
2020
Q3 		$4.43M Buy
+193,626
New +$4.77M 0.01% 761
2020
Q2 		– Sell
-170,545
Closed -$2.38M – 2350
2020
Q1 		$2.38M Buy
170,545
+128,734
+308% +$2.55M 0.01% 837
2019
Q4 		$952K Buy
+41,811
New +$698K ﹤0.01% 1282
2019
Q1 		– Sell
-403,452
Closed -$5.98M – 2220
2018
Q4 		$5.98M Sell
403,452
-160,022
-28% -$2.66M 0.02% 687
2018
Q3 		$13.9M Buy
+563,474
New +$12.2M 0.03% 460
2016
Q1 		– Sell
-7,500
Closed -$340K – 2161
2015
Q4 		$340K Hold
7,500
– – ﹤0.01% 1384
2015
Q3 		$282K Buy
+7,500
New +$344K ﹤0.01% 1433

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Federated Hermes's RCKT Position: Q2 2026 in Review

Federated Hermes increased its Rocket Pharmaceuticals (RCKT) stake by 125% in Q2 2026, buying an estimated $4.26M and bringing the position to 2,304,207 shares worth $7.88M. The position accounts for 0.01% of the portfolio, ranked #758.

Federated Hermes first reported a position in RCKT in Q3 2015 and has held it in 22 quarters since. The position peaked at $13.9M in Q3 2018. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Federated Hermes held 2,304,207 shares of Rocket Pharmaceuticals worth $7.88M as of Q2 2026.
  • Federated Hermes bought 1,280,460 Rocket Pharmaceuticals shares in Q2 2026, an estimated $4.26M.
  • Rocket Pharmaceuticals made up 0.01% of Federated Hermes's portfolio in Q2 2026, its #758 holding.
  • Federated Hermes first reported a position in Rocket Pharmaceuticals in Q3 2015 and has held it in 22 quarters since.
  • Federated Hermes's Rocket Pharmaceuticals position peaked at $13.9M in Q3 2018.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.